Non small cell lung cancer overview (David Ross Camidge)
- Watch video(FLV)
This section includes information and resources about Cancer for journalists: Boehringer Ingelheim press releases, background information, related press kits and a collection of images and videos.
Rare disease day: Boehringer Ingelheim announces initiation of pivotal trial investigating volasertib* in patients with acute myeloid leukaemia
U.S. FDA Grants Priority Review to Boehringer Ingelheim’s Afatinib* NDA for EGFR Mutation-Positive Advanced NSCLC
Boehringer Ingelheim to initiate Phase III study in leukaemia with its compound volasertib* based on positive Phase II results
Boehringer Ingelheim submits first oncology compound, afatinib* for European approval- For NON-US media only
Afatinib* delivers unprecedented first line efficacy in patients with EGFR mutation positive lung cancer in registration trial- For NON-US media only